Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

Inclusion Criteria: * Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment. * Corresponding to one of the two groups below: * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy. * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment * Affiliation to a social security scheme * Patient who signed the genetic consent form Exclusion Criteria: * Minor patient * Pregnant patient * Patient under guardianship or conservatorship * Patients who object to the collection of their medical/paramedical data * Patient for whom the center does not have biological material for genomic analysis (FFPE block) * Patient under administrative, judicial decision or AME (State Medical Aid)